var title_f6_19_6448="Push off demonstrating winging of scapula";
var content_f6_19_6448=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1070px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/83145/Push_off_demo_winging_video.mp4?title=Push+off+demonstrating+winging+of+scapula\" style=\"width:480px;height:368px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Wall push-off demonstrating winging of scapula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 311px; height: 401px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Having the patient push from a wall can help accentuate scapular winging, as demonstrated in this video clip. Note how the right scapula is elevated and protracted.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Simons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_19_6448=[""].join("\n");
var outline_f6_19_6448=null;
var title_f6_19_6449="Salivary gland anatomy";
var content_f6_19_6449=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of the salivary glands and ducts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The three major salivary glands are the parotid, submandibular, and sublingual glands. Stensen's duct drains the parotid gland opposite the upper second molar. Wharton's duct drains the submandibular and some of the sublingual glands into the floor of the mouth near the frenulum of the tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_19_6449=[""].join("\n");
var outline_f6_19_6449=null;
var title_f6_19_6450="Etilefrine: International drug information";
var content_f6_19_6450=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Etilefrine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1978767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adrenam (DE);",
"     </li>",
"     <li>",
"      Bioflutin-N (DE);",
"     </li>",
"     <li>",
"      Cardanat (DE);",
"     </li>",
"     <li>",
"      Cardialgine (DE);",
"     </li>",
"     <li>",
"      Circupon (AT, CH, DE);",
"     </li>",
"     <li>",
"      Circuvit E (DE);",
"     </li>",
"     <li>",
"      Confidol (DE);",
"     </li>",
"     <li>",
"      Corcanfol (AR);",
"     </li>",
"     <li>",
"      Effortil (AR, AT, BE, CH, CY, DE, FI, FR, HR, IT, LU, NO, PT, SE);",
"     </li>",
"     <li>",
"      Effortil PL (BE, LU);",
"     </li>",
"     <li>",
"      Efortil (BR, ES);",
"     </li>",
"     <li>",
"      Ethyfron (JP);",
"     </li>",
"     <li>",
"      Eti-Puren (DE);",
"     </li>",
"     <li>",
"      etil von ct (DE);",
"     </li>",
"     <li>",
"      Etilefrin (DE);",
"     </li>",
"     <li>",
"      Etilefrin AL (DE);",
"     </li>",
"     <li>",
"      Etilefrin-Neosan (DE);",
"     </li>",
"     <li>",
"      Etilefrin-ratiopharm (DE);",
"     </li>",
"     <li>",
"      Etilefrina (AR);",
"     </li>",
"     <li>",
"      Etilefrina Denver Farma (AR);",
"     </li>",
"     <li>",
"      Etilefrina Fabra (AR);",
"     </li>",
"     <li>",
"      Etilefrina Larjan (AR);",
"     </li>",
"     <li>",
"      Hishiherin-S (JP);",
"     </li>",
"     <li>",
"      Kertasin (AR);",
"     </li>",
"     <li>",
"      Kreislauf Katovit (DE);",
"     </li>",
"     <li>",
"      Logomed Kreislauf-Tabletten (DE);",
"     </li>",
"     <li>",
"      Mandroton (DE);",
"     </li>",
"     <li>",
"      Menegradil (AR);",
"     </li>",
"     <li>",
"      Pulsamin (JP);",
"     </li>",
"     <li>",
"      Theoral (JP);",
"     </li>",
"     <li>",
"      Thomasin (DE);",
"     </li>",
"     <li>",
"      Tonus-Forte (DE);",
"     </li>",
"     <li>",
"      Tonustab (DE);",
"     </li>",
"     <li>",
"      Tulupressin (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1978760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Etilefrine Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alpha/Beta Agonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of symptomatic or orthostatic hypotension",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adults: Oral: 5-10 mg 3 times/day or 25 mg long-acting capsule once or twice daily",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, long acting: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: 5 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10379 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-1360C6F796-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_19_6450=[""].join("\n");
var outline_f6_19_6450=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978767\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978760\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978762\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978765\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978761\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821181\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978764\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10379\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10379|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_19_6451="Pyogenic granuloma dermoscopy";
var content_f6_19_6451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Pyogenic granuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clinical (left) and dermoscopic (right) image of pyogenic granuloma. On dermoscopy, pyogenic granulomas typically appear as pink homogeneous papules with a white collarette and white intersecting lines representing the fibrous septa seen at histopathology. In a minority of cases, as in the one shown in this picture, a bluish homogeneous structure can be seen. These cases are often clinically and dermoscopically misdiagnosed as melanomas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. Ashfaq Marghoob.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_19_6451=[""].join("\n");
var outline_f6_19_6451=null;
var title_f6_19_6452="Toxic conjunctivitis";
var content_f6_19_6452=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Toxic conjunctivitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/19/6452/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/19/6452/contributors\">",
"     Pedram Hamrah, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/19/6452/contributors\">",
"     Reza Dana, MD, MPH, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/19/6452/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/19/6452/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/19/6452/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/19/6452/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/19/6452/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/19/6452/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are five main types of ocular allergy: seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and giant papillary conjunctivitis (GPC). Toxic conjunctivitis (also called toxic keratoconjunctivitis) is not allergic in nature, but it is frequently confused with allergic ocular disease. It implies direct damage to ocular tissues from an offending agent, usually a preservative or medication. The toxic agent can cause a papillary or follicular response in the conjunctiva with chronic use, and the conjunctiva can become chemotic, edematous, and hyperemic. Toxic conjunctivitis is reviewed here. The various forms of ocular allergy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=see_link\">",
"     \"Allergic conjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37352?source=see_link\">",
"     \"Vernal keratoconjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37910?source=see_link\">",
"     \"Atopic keratoconjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5062?source=see_link\">",
"     \"Giant papillary conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxic conjunctivitis typically occurs with protracted use of topical ocular medications [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6452/abstract/1\">",
"     1",
"    </a>",
"    ]. The reaction may take days to years to develop. There also appears to be a dose-response effect with regard to the preservative concentration and total amount of preservative-containing medications used [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6452/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, toxic ocular reactions are most frequently reported in patients with glaucoma, who are on lifelong therapy with multiple medications [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6452/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results from a monkey model and human corneal epithelial cell culture suggest that preservatives in ophthalmic solutions are unlikely to cause significant direct toxicity to epithelium of otherwise normal cornea [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6452/abstract/4\">",
"     4",
"    </a>",
"    ]. However, studies in rabbit models consistently demonstrate ocular surface toxicity with topical preservative-containing medications [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6452/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. In one study, patients with dry eyes were at greater risk for the development of toxic papillary reactions than those without dry eyes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6452/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preservatives in eye medications, contact lens solutions, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    are the most common causes of toxic ocular reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6452/abstract/7\">",
"     7",
"    </a>",
"    ]. The most common types of preservatives include benzalkonium chloride (BAK or BAC), thimerosal, chlorobutanol, sodium perborate, and stabilized oxychloro complex (SOC). All of these can cause toxic, irritant, or hypersensitivity reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6452/abstract/8\">",
"     8",
"    </a>",
"    ]. However, in rabbit models, the newer generation SOC is less cytotoxic than the other preservatives [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6452/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of findings are seen in patients treated with preserved medications compared with those using preservative-free therapies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Goblet cell density is decreased in conjunctival epithelium [",
"      <a class=\"abstract\" href=\"UTD.htm?6/19/6452/abstract/9\">",
"       9",
"      </a>",
"      ] and tear film break-up time is reduced [",
"      <a class=\"abstract\" href=\"UTD.htm?6/19/6452/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Subclinical inflammation of conjunctival epithelium is commonly seen [",
"      <a class=\"abstract\" href=\"UTD.htm?6/19/6452/abstract/3\">",
"       3",
"      </a>",
"      ]. Biopsies show an increase in surface expression of inflammatory markers and mediators, including HLA-DR, intercellular adhesion molecule-1 (ICAM-1), and chemokine receptors CCR4 and CCR5 [",
"      <a class=\"abstract\" href=\"UTD.htm?6/19/6452/abstract/3,9,10\">",
"       3,9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Additional histopathologic findings include epithelial keratinization, squamous metaplasia, subconjunctival fibrosis, and increased apoptosis in the ocular epithelium [",
"      <a class=\"abstract\" href=\"UTD.htm?6/19/6452/abstract/3,10\">",
"       3,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Toxic reactions to just about every eye medication have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6452/abstract/11-17\">",
"     11-17",
"    </a>",
"    ]. Among the more common toxic medicines are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Aminoglycoside antibiotics, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"     </li>",
"     <li>",
"      Antiviral agents, such as trifluorothymidine (Viroptic&reg;) and idoxuridine (Herplex&reg;)",
"     </li>",
"     <li>",
"      Glaucoma drops, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/32/15877?source=see_link\">",
"       brimonidine",
"      </a>",
"      (Alphagan&reg;),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31776?source=see_link\">",
"       timolol",
"      </a>",
"      maleate (Timoptic&reg;), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"     </li>",
"     <li>",
"      Topical anesthetics",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cosmetics, such as mascara, creams, or hair spray may also cause toxic ocular reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6452/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SIGNS AND SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conjunctival injection, chemosis, mucus discharge, papillary reaction of the palpebral conjunctiva, and itching are common. The eyelids can become swollen, thickened, and excoriated.",
"   </p>",
"   <p>",
"    In mild cases of toxic conjunctivitis, the cornea will show punctate epithelial staining with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    dye application. In more severe cases, large epithelial erosions and corneal ulceration may develop. Degenerated epithelium can roll up and form pseudodendrites that are sometimes confused with herpetic dendrites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should take a thorough history of all topical ocular medications used and their duration of usage. A common history is that the original eye condition improved upon initial treatment, but the eye symptoms worsened with continued use. The diagnosis is confirmed when the eyedrops are discontinued and the clinical manifestations resolve. Patch testing is rarely helpful for identification of the culprit, since toxic conjunctivitis is a local reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis includes the various forms of ocular allergy (seasonal and perennial allergic conjunctivitis, vernal and atopic keratoconjunctivitis, and giant papillary conjunctivitis), allergic reactions to ophthalmic medications, and conjunctivitis medicamentosa. Toxic conjunctivitis can occur in addition to one of these conditions, since most of these patients are treated with topical ophthalmic medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=see_link\">",
"     \"Allergic conjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37352?source=see_link\">",
"     \"Vernal keratoconjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37910?source=see_link\">",
"     \"Atopic keratoconjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5062?source=see_link\">",
"     \"Giant papillary conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The eyelids can become swollen, thickened, and excoriated in toxic conjunctivitis. In contrast, these eyelid findings are unusual in the various forms of ocular allergy (the exception being atopic keratoconjunctivitis). In addition, ocular allergy more commonly presents with itching. Many times the symptoms of toxic conjunctivitis are associated and coincide with use of eye drops.",
"     </li>",
"     <li>",
"      Hypersensitivity reactions to topical ocular medications typically occur early in the course of treatment, whereas toxic reactions usually occur after prolonged use.",
"     </li>",
"     <li>",
"      Conjunctivitis medicamentosa is caused by overuse of vasoconstricting eyedrops [",
"      <a class=\"abstract\" href=\"UTD.htm?6/19/6452/abstract/20\">",
"       20",
"      </a>",
"      ]. It presents with increased conjunctival injection and rebound hyperemia that occurs when the medication is discontinued. It is thought to be similar to rhinitis medicamentosa that occurs with topical nasal decongestants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition of the diagnosis of toxic conjunctivitis and removal of the offending agent(s) are imperative to the success of treating this condition. Stopping as many topical medications as feasible is a good first step. A preservative-free preparation should be used if a specific medication is required and preservative toxicity is suspected. An oral medication may be offered in situations in which a topical medication is causing toxicity, if that option is available. Cold compresses and preservative-free",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    or ointments may help with ocular irritation. The patient should be monitored closely by an ophthalmologist after the suspected agent is stopped if an infectious process is possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Toxic conjunctivitis is not allergic in nature, but it is frequently confused with allergic ocular disease. It implies direct damage to ocular tissues from an offending agent, usually a preservative or medication. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Toxic conjunctivitis most commonly occurs in patients on long-term therapy with multiple preservative-containing topical ocular medications, such as those with glaucoma. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conjunctival hyperemia is the most common manifestation. The eyelids and cornea may also be involved. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Signs and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A common history is that the original eye condition improved upon initial treatment, but the eye symptoms worsened with continued use. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis includes the various forms of ocular allergy, hypersensitivity reactions to ophthalmic medications, and conjunctivitis medicamentosa. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=see_link\">",
"       \"Allergic conjunctivitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37352?source=see_link\">",
"       \"Vernal keratoconjunctivitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37910?source=see_link\">",
"       \"Atopic keratoconjunctivitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5062?source=see_link\">",
"       \"Giant papillary conjunctivitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment involves discontinuing the suspected offending agent(s) and switching to preservative-free topical therapies or oral medications when possible if continued therapy is required. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6452/abstract/1\">",
"      Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001; 18:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6452/abstract/2\">",
"      Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007; 17:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6452/abstract/3\">",
"      Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol 2008; 86:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6452/abstract/4\">",
"      Khoh-Reiter S, Jessen BA. Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. BMC Ophthalmol 2009; 9:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6452/abstract/5\">",
"      Liang H, Baudouin C, Pauly A, Brignole-Baudouin F. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br J Ophthalmol 2008; 92:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6452/abstract/6\">",
"      Wilson FM 2nd. Adverse external ocular effects of topical ophthalmic therapy: an epidemiologic, laboratory, and clinical study. Trans Am Ophthalmol Soc 1983; 81:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6452/abstract/7\">",
"      Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Saf 2008; 31:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6452/abstract/8\">",
"      Hong J, Bielory L. Allergy to ophthalmic preservatives. Curr Opin Allergy Clin Immunol 2009; 9:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6452/abstract/9\">",
"      Pisella PJ, Lala E, Parier V, et al. [Effect of preservatives on the conjunctiva: a comparative study of beta-blocker eye drops with and without preservatives in glaucoma patients]. J Fr Ophtalmol 2003; 26:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6452/abstract/10\">",
"      Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol 2005; 5:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6452/abstract/11\">",
"      FEDUKOWICZ H, WISE GN, ZARET MM. Toxic conjunctivitis due to antibiotics. Am J Ophthalmol 1955; 40:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6452/abstract/12\">",
"      Benjamin KW. Toxicity of ocular medications. Int Ophthalmol Clin 1979; 19:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6452/abstract/13\">",
"      Chen HT, Chen KH, Hsu WM. Toxic keratopathy associated with abuse of low-dose anesthetic: a case report. Cornea 2004; 23:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6452/abstract/14\">",
"      Imperia PS, Lazarus HM, Dunkel EC, et al. An in vitro study of ophthalmic antiviral agent toxicity on rabbit corneal epithelium. Antiviral Res 1988; 9:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6452/abstract/15\">",
"      Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004; 23:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6452/abstract/16\">",
"      Pisella PJ, Fillacier K, Elena PP, et al. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic Res 2000; 32:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6452/abstract/17\">",
"      Coles WH. Pilocarpine toxicity. Effects on the rabbit corneal endothelium. Arch Ophthalmol 1975; 93:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6452/abstract/18\">",
"      Ciolino JB, Mills DM, Meyer DR. Ocular manifestations of long-term mascara use. Ophthal Plast Reconstr Surg 2009; 25:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6452/abstract/19\">",
"      S&aacute;nchez Palacios A, Shaman F, Garc&aacute; JA, S&aacute;nchez Palacios MA. [Prevalence of cosmetic sensitivity among beauticians]. Allergol Immunopathol (Madr) 1995; 23:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6452/abstract/20\">",
"      Spector SL, Raizman MB. Conjunctivitis medicamentosa. J Allergy Clin Immunol 1994; 94:134.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5555 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-D795AC79FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_19_6452=[""].join("\n");
var outline_f6_19_6452=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SIGNS AND SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=related_link\">",
"      Allergic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37910?source=related_link\">",
"      Atopic keratoconjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5062?source=related_link\">",
"      Giant papillary conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37352?source=related_link\">",
"      Vernal keratoconjunctivitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_19_6453="Clavicle PI";
var content_f6_19_6453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Clavicle (collarbone)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 603px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows the location of the clavicle, also called the collarbone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_19_6453=[""].join("\n");
var outline_f6_19_6453=null;
var title_f6_19_6454="Anagrelide: Drug information";
var content_f6_19_6454=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Anagrelide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/15/29940?source=see_link\">",
"    see \"Anagrelide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F135406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Agrylin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F135407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Agrylin&reg;;",
"     </li>",
"     <li>",
"      Dom-Anagrelide;",
"     </li>",
"     <li>",
"      Mylan-Anagrelide;",
"     </li>",
"     <li>",
"      PMS-Anagrelide;",
"     </li>",
"     <li>",
"      Sandoz-Anagrelide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F135424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Phosphodiesterase-3 Enzyme Inhibitor;",
"     </li>",
"     <li>",
"      Phospholipase A",
"      <sub>",
"       2",
"      </sub>",
"      Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F135409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Thrombocythemia:",
"     </b>",
"     Oral: Initial: 0.5 mg 4 times/day or 1 mg twice daily (most patients will experience adequate response at dose ranges of 1.5-3 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Maintain initial dose for &ge;1 week, then adjust to the lowest effective dose to reduce and maintain platelet count &lt;600,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ideally to the normal range; the dose must not be increased by &gt;0.5 mg/day in any 1 week; maximum dose: 10 mg/day or 2.5 mg/dose",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F135418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Thrombocythemia:",
"     </b>",
"     Oral: Initial: 0.5 mg/day (range: 0.5 mg 1-4 times/day); see &ldquo;",
"     <b>",
"      Note",
"     </b>",
"     &rdquo; in adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F135410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8112334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment required in renal insufficiency; monitor closely.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F135411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate impairment: Initial: 0.5 mg once daily; maintain for at least 1 week with careful monitoring of cardiovascular status; the dose must not be increased by &gt;0.5 mg/day in any 1 week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F135388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 0.5 mg, 1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Agrylin&reg;: 0.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F135374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5172803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F135391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of thrombocythemia associated with myeloproliferative disorders (eg, chronic myelogenous leukemia, essential thrombocythemia, polycythemia vera, myeloid metaplasia with myelofibrosis, or other myeloproliferative disorder) to reduce the risk of thrombosis and reduce associated symptoms (including thrombo-hemorrhagic events)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6884123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Anagrelide may be confused with anastrozole",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F135422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Palpitation (26%), edema (21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (44%), dizziness (15%), pain (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (26%), nausea (17%), abdominal pain (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (9%), chest pain (8%), tachycardia (8%), angina, arrhythmia, HF, hypertension, orthostatic hypotension, syncope, thrombosis, vasodilatation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (9%), malaise (6%), amnesia, chills, confusion, depression, insomnia, migraine, nervousness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (8%), pruritus (6%), alopecia, bruising, photosensitivity, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; skeletal: Dehydration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Flatulence (10%), vomiting (10%), anorexia (8%), dyspepsia (5%), aphthous stomatitis, constipation, eructation, gastritis, GI distress, GI hemorrhage, melena",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Dysuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (9%; grades 3/4: 5%), anemia, hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (6%), paresthesia (6%), arthralgia, leg cramps, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Amblyopia, diplopia, visual field abnormality",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal abnormality (2%), renal failure (1%), hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (7%), cough (6%), asthma, bronchitis, epistaxis, pneumonia, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome, lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Atrial fibrillation, cardiomegaly, cardiomyopathy, cerebrovascular accident, complete heart block, gastric/duodenal ulceration, hepatotoxicity, interstitial lung disease (allergic alveolitis, eosinophilic pneumonia, interstitial pneumonitis); leukocyte count increased, liver enzymes (ALT, AST) increased, MI, pancreatitis, pericarditis, pericardial effusion, pleural effusion, pulmonary fibrosis, pulmonary hypertension, pulmonary infiltrates, seizure, tubulointerstitial nephritis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F135394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F135378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary disorders: Interstitial lung disease (including allergic alveolitis, eosinophilic pneumonia, and interstitial pneumonitis) has been associated with use. Onset is from 1 week to several years, usually presenting with progressive dyspnea with lung infiltrations; symptoms usually improve after discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal abnormalities: Renal abnormalities (including renal failure) have been observed with anagrelide use; may be associated with pre-existing renal impairment, although dosage adjustment due to renal insufficiency was not required. Monitor closely in patients with renal insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with known or suspected heart disease; tachycardia, palpitation, vasodilation, orthostatic hypotension, and heart failure have been reported. Pretreatment cardiovascular evaluation and careful monitoring during treatment is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild-to-moderate hepatic impairment; dosage reduction and careful cardiovascular monitoring are required for moderate impairment; use is contraindicated in severe hepatic impairment. Monitor liver function prior to and during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F135420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F135383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F135404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: No clinically significant effect on absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid herbs with anticoagulant/antiplatelet properties (alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose oil, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng [American], ginseng [Panax], ginseng [Siberian], grape seed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe [S-adenosylmethionine], sweet clover, turmeric, white willow); may enhance the adverse effect of antiplatelets agents.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F135384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F135397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies; however, decreased pup survival was noted. Use of anagrelide during pregnancy is limited. The manufacturer recommends effective contraception in women of childbearing potential. Use during pregnancy only if potential benefit to mother outweighs possible risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F135413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5172802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F135396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Agrylin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $835.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Anagrelide HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $585.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $1171.35",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F135386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Platelet count (every 2 days during the first week of treatment and at least weekly until the maintenance dose is reached; continue to monitor after cessation of treatment); CBC with differential (monitor closely during first 2 weeks of treatment), liver function (ALT and AST; baseline and during treatment), BUN, and serum creatinine (monitor closely during first weeks of treatment); blood pressure; cardiovascular exam (pretreatment; monitor during therapy). Monitor for thrombosis or bleeding.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F135398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Agrelid (AR);",
"     </li>",
"     <li>",
"      Agrylin (AU, HK, ID, IL, KP, PH, SG, TH, TW);",
"     </li>",
"     <li>",
"      Thromboreductin (AT, BG, CZ, HK, HN, MY, TH, TR);",
"     </li>",
"     <li>",
"      Xagrid (AT, BE, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F135377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anagrelide appears to inhibit cyclic nucleotide phosphodiesterase and the release of arachidonic acid from phospholipase, possibly by inhibiting phospholipase A",
"     <sub>",
"      2",
"     </sub>",
"     . It also causes a dose-related reduction in platelet production, which results from decreased megakaryocyte hypermaturation (disrupts the postmitotic phase of maturation).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F135393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Onset of action: Initial: Within 7-14 days; complete response (platelets &le;600,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ): 4-12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 6-24 hours; upon discontinuation, platelet count begins to rise within 4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, partially via CYP1A2; to two major metabolites, RL603 and 3-hydroxy anagrelide",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination, plasma: 1.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;1% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Campbell PJ, Bareford D, Erber WN, et al, &ldquo;Reticulin Accumulation in Essential Thrombocythemia: Prognostic Significance and Relationship to Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(18):2991-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/19/6454/abstract-text/19364963/pubmed\" id=\"19364963\" target=\"_blank\">",
"        19364963",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doubek M, Brychtova Y, Doubek R, et al, &ldquo;Anagrelide Therapy in Pregnancy: Report of a Case of Essential Thrombocythemia,&rdquo;",
"      <i>",
"       Ann Hematol",
"      </i>",
"      , 2004, 83(11):726-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/19/6454/abstract-text/15278298/pubmed\" id=\"15278298\" target=\"_blank\">",
"        15278298",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fruchtman SM, Petitt RM, Gilbert HS, et al, &ldquo;Anagrelide: Analysis of Long-Term Efficacy, Safety and Leukemogenic Potential in Myeloproliferative Disorders,&rdquo;",
"      <i>",
"       Leuk Res",
"      </i>",
"      , 2005, 29(5):481-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/19/6454/abstract-text/15755500/pubmed\" id=\"15755500\" target=\"_blank\">",
"        15755500",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harrison CN, Campbell PJ, Buck G, et al, &ldquo;Hydroxyurea Compared With Anagrelide in High-Risk Essential Thrombocythemia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(1):33-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/19/6454/abstract-text/16000354/pubmed\" id=\"16000354\" target=\"_blank\">",
"        16000354",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pescatore SL and Lindley C, &ldquo;Anagrelide: A Novel Agent for the Treatment of Myeloproliferative Disorders,&rdquo;",
"      <i>",
"       Expert Opin Pharmacother",
"      </i>",
"      , 2000, 1(3):537-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/19/6454/abstract-text/11249536/pubmed\" id=\"11249536\" target=\"_blank\">",
"        11249536",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silver RT, &ldquo;Anagrelide is Effective in Treating Patients With Hydroxyurea-Resistant Thrombocytosis in Patients With Chronic Myeloid Leukemia,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2005, 19(1):39-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/19/6454/abstract-text/15510207/pubmed\" id=\"15510207\" target=\"_blank\">",
"        15510207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steurer M, Gastl G, Jedrzejczak WW, et al, Anagrelide for Thrombocytosis in Myeloproliferative Disorders: A Prospective Study to Assess Efficacy and Adverse Event Profile,&rdquo; Cancer, 2004, 101(10):2239-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/19/6454/abstract-text/15476273/pubmed\" id=\"15476273\" target=\"_blank\">",
"        15476273",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tefferi A and Vardiman JW, &ldquo;Classification and Diagnosis of Myeloproliferative Neoplasms: The 2008 World Health Organization Criteria and Point-of-Care Diagnostic Algorithms,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2008, 22(1):14-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/19/6454/abstract-text/17882280/pubmed\" id=\"17882280\" target=\"_blank\">",
"        17882280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8593 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.172.26-E56BECDC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_19_6454=[""].join("\n");
var outline_f6_19_6454=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135406\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135407\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135424\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135409\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135418\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135410\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8112334\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135411\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135388\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135374\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5172803\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135391\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6884123\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135422\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135394\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135378\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135420\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135383\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135404\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135384\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135397\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135413\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5172802\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135396\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135386\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135398\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135377\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135393\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8593\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8593|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/15/29940?source=related_link\">",
"      Anagrelide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_19_6455="Vulvar and vaginal intraepithelial neoplasia in HIV-infected women";
var content_f6_19_6455=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vulvar and vaginal intraepithelial neoplasia in HIV-infected women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/19/6455/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/19/6455/contributors\">",
"     William R Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/19/6455/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/19/6455/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/19/6455/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/19/6455/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/19/6455/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with human immunodeficiency virus (HIV) infection are at an increased risk of vulvar and vaginal neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6455/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. As with cervical neoplasia, the incidence and severity of vulvar and vaginal premalignant and malignant disease appear to correlate with worsening immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6455/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Furthermore, despite standard therapy, HIV-infected women with vulvar or vaginal neoplasia have higher rates of persistence and recurrence than the general population, again similar to cervical neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6455/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Screening, diagnosis, and treatment for vulvar and vaginal intraepithelial neoplasia in HIV-infected women will be reviewed here. Vulvar and vaginal neoplasia in the general population are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=see_link\">",
"     \"Vulvar intraepithelial neoplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5560?source=see_link\">",
"     \"Vaginal intraepithelial neoplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Vulvar Oncology Subcommittee of the International Society for the Study of Vulvar Diseases (ISSVD) published a classification system for vulvar intraepithelial neoplasia (VIN) in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6455/abstract/11\">",
"     11",
"    </a>",
"    ]. The term VIN was limited to histologically high-grade squamous lesions (formerly termed VIN 2 and VIN 3), for which treatment is indicated to prevent progression to cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6455/abstract/11\">",
"     11",
"    </a>",
"    ]. Lesions previously referred to as VIN 1 were no longer classified as VIN. This topic review will adhere to the 2004 ISSVD nomenclature except when data are reported from studies that used the previous classification. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=see_link&amp;anchor=H2#H2\">",
"     \"Vulvar intraepithelial neoplasia\", section on 'Terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;VIN and vaginal intraepithelial neoplasia (VAIN) are precursors to vulvar and vaginal cancer and are more common in women infected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6455/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. In the general United States population, the estimated incidence of VIN and VAIN is 2.9 and 0.2 to 0.3 per 100,000 women, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=see_link&amp;anchor=H3#H3\">",
"     \"Vulvar intraepithelial neoplasia\", section on 'Incidence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5560?source=see_link&amp;anchor=H3#H3\">",
"     \"Vaginal intraepithelial neoplasia\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of VIN and VAIN in HIV-infected women has not been extensively studied, but the available data are consistent with increased risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study, 5 of 385 HIV-infected women followed for a median of 3.2 years developed new high-grade",
"      <span class=\"nowrap\">",
"       vulvar/perianal",
"      </span>",
"      intraepithelial neoplasia compared with 0 of 341 women without HIV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?6/19/6455/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another prospective study, the incidence of VAIN at six year follow-up was 3 of 192 HIV-infected women compared with 0 of 88 women without HIV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?6/19/6455/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective study (n = 410) of women who had undergone hysterectomy found a statistically significantly increased rate of VAIN 2 or vaginal cancer in women with compared to without HIV infection (0.2 versus 0.01 per 100 person-years) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/19/6455/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human papilloma virus (HPV) infection is the primary etiology of vulvar, vaginal, and cervical neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6455/abstract/16\">",
"     16",
"    </a>",
"    ]. HPV and HIV interact in several ways that are relevant to VIN and VAIN:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HPV and HIV infection share a sexual route of transmission, and therefore, the vulnerable populations often coincide.",
"     </li>",
"     <li>",
"      HIV-mediated immunosuppression results in exacerbation of HPV infection, and an increased incidence and severity of high-grade vulvar and vaginal lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?6/19/6455/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HIV infection appears to impair local mechanisms of lower genital tract immunity, as demonstrated by a decreased Langerhans cell density in vulvar tissue in HIV-infected women [",
"      <a class=\"abstract\" href=\"UTD.htm?6/19/6455/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HPV vaccination decreases the incidence of vulvar and vaginal neoplasia. This was demonstrated in a randomized trial of 5455 healthy women ages 16 to 24 years with no history of genital warts or abnormal cervical cytology who were assigned to receive the quadrivalent HPV vaccine (HPV types 6, 11, 16, 18) or a placebo injection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6455/abstract/20\">",
"     20",
"    </a>",
"    ]. At an average of three-year follow-up, there were fewer cases of grade 2 or 3 VIN or VAIN in women in the vaccine group than in the placebo group (0.1 versus 0.2 percent); however, the trial did not have sufficient statistical power to assess whether the difference was significant (efficacy 62 percent, 95% CI &lt;0-89). At the start of the study, 13 to 14 percent of women tested positive for infection with one or more of the HPV types included in the vaccine. Excluding these women from the analysis did not alter the magnitude of the effect of vaccination; the rates of grade 2 or 3 VIN or VAIN for the vaccine and placebo groups were 0.04 versus 0.1 percent. Additional details of this trial are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13480?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical trials of human papillomavirus vaccines\", section on 'The FUTURE 1 trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The safety or efficacy of the currently available HPV types 16 and 18 vaccine in preventing vulvar or vaginal neoplasia in HIV-infected women is unknown. It appears that it can be used in immunosuppressed patients, since it is not a live vaccine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link&amp;anchor=H5968486#H5968486\">",
"     \"Recommendations for the use of human papillomavirus vaccines\", section on 'Immunosuppressed or immunocompromised hosts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the vaccine may be less effective since the distribution of HPV subtypes in women with HIV infection is typically different from that seen in HIV-negative women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18665?source=see_link&amp;anchor=H12#H12\">",
"     \"Preinvasive and invasive cervical neoplasia in HIV-infected women\", section on 'Future directions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology of human papillomavirus infections\", section on 'Epidemiology in females'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given that HPV vaccination may offer some benefit to women with HIV infection and is not contraindicated in women with immunosuppression, we suggest HPV vaccination in HIV-infected women. Either the quadrivalent (HPV types 6, 11, 16, 18) or bivalent (HPV types 16 and 18) formulation can be used, but the quadrivalent vaccine offers the additional potential benefit of prevention of anogenital warts associated with HPV types 6 and 11, which can be extensive in immunosuppressed patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link&amp;anchor=H6#H6\">",
"     \"Condylomata acuminata (anogenital warts)\", section on 'HIV infected individuals'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preexisting lower genital neoplasia is not a contraindication to HPV vaccination, since an individual may be infected with one, but not all of the HPV subtypes included in the vaccine. Type-specific testing for HPV 16 and 18 is not useful for identifying women who should not receive the vaccine, since HPV infection can be transient and it is not known if previous HPV infection is protective against reinfection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link&amp;anchor=H13#H13\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\", section on 'HPV testing result reporting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of VIN and VAIN in HIV-infected women are the same as for women without HIV infection. Approximately 50 percent of women with VIN are asymptomatic. In symptomatic women, the most common complaint is vulvar pruritus; other presentations include perineal pain or burning, dysuria, a visible lesion, or a palpable abnormality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=see_link&amp;anchor=H7#H7\">",
"     \"Vulvar intraepithelial neoplasia\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    VAIN is nearly always asymptomatic, but some women present with postcoital spotting or vaginal discharge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5560?source=see_link&amp;anchor=H7#H7\">",
"     \"Vaginal intraepithelial neoplasia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;VIN and VAIN are rare conditions and screening is not routinely performed in the general population. Although HIV-infected women have an increased risk of these conditions, there are no data or guidelines regarding screening HIV-infected women for vulvar or vaginal cancer.",
"   </p>",
"   <p>",
"    In contrast, the specific cervical cancer screening recommendations for HIV-infected women are that they undergo screening twice in the first year after diagnosis of HIV infection and then annually, provided the test results are normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36934?source=see_link&amp;anchor=H2#H2\">",
"     \"Screening for cervical cancer in HIV infected women\", section on 'Cervical cytology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HIV-infected women should, therefore, undergo a pelvic examination annually, at minimum. We suggest that HIV-infected women undergo a careful vulvar and vaginal examination whenever a pelvic examination is performed for cervical cancer screening for another indication (with the exception of focused examinations during which vulvar or vaginal examination for neoplasia would not be practical).",
"   </p>",
"   <p>",
"    In our practice, we examine women who are immunosuppressed (CD4 cell count",
"    <span class=\"nowrap\">",
"     &lt;200/mm3)",
"    </span>",
"    or have a viral load of &ge;500",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    at least every six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;VIN and VAIN are histologic diagnoses based upon vulvar or vaginal biopsy. Biopsy may be directed by gross visual examination of lesions or by examination under magnification with a colposcope or hand-held magnifying device.",
"   </p>",
"   <p>",
"    Indications for a diagnostic evaluation are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinical manifestations of VIN or VAIN",
"     </li>",
"     <li>",
"      Vaginal or vulvar lesion that are suspicious for neoplasia",
"     </li>",
"     <li>",
"      Abnormal cervical cytology, if a cervical lesion is not identified",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Aspects of evaluation for VIN and VAIN that are specific to women with HIV infection are described here. General techniques for vulvar and vaginal examination and biopsy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37349?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnostic evaluation of vulvar lesions\", section on 'Physical examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37349?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnostic evaluation of vulvar lesions\", section on 'Diagnostic evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5560?source=see_link&amp;anchor=H7#H7\">",
"     \"Vaginal intraepithelial neoplasia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Vulvar neoplasia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Vulvar examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete examination is performed of areas with potential squamous neoplasia. In HIV-infected women, this includes examination of the vulva as well as the perineum and perianal areas.",
"   </p>",
"   <p>",
"    VIN is highly variable in appearance and may be a subtle visual finding. In the general population, VIN is commonly located between the 3:00 and 9:00 positions along the labia minora and the introitus (mapping vulvar sites according to locations around a clock face). In HIV-infected women, VIN may be more extensive and scattered. Lesions may involve the clitoris, urethra, anus and intergluteal cleft and can easily be overlooked [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6455/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Characteristics of vulvar lesions and techniques for vulvar examination and evaluation of anal lesions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37349?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnostic evaluation of vulvar lesions\", section on 'Physical examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11670?source=see_link&amp;anchor=H5#H5\">",
"     \"Evaluation of the HIV-infected patient with anorectal symptoms\", section on 'Diagnostic studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Vulvar colposcopy and biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colposcopy or examination using a hand-held magnifying glass may be useful for some vulvar lesions. We use magnification to examine any small lesion that is visible but is difficult to see with the unaided eye. Biopsy is performed of all lesions that are not obviously benign (eg, epidermoid cysts, often erroneously referred to as sebaceous cysts). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20618?source=see_link&amp;anchor=H8#H8\">",
"     \"Differential diagnosis of vulvar lesions\", section on 'Cysts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The techniques for vulvar colposcopy and biopsy are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=see_link&amp;anchor=H17#H17\">",
"     \"Colposcopy\", section on 'Vulvar colposcopy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37349?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnostic evaluation of vulvar lesions\", section on 'Biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vaginal neoplasia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Vaginal examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the vaginal examination; attempts are made to visualize lesions while using a speculum and to palpate lesions with a manual examination. VAIN may be difficult to visualize without magnification, and is therefore usually detected with cytology. When it is visible, it is generally white in appearance, with sharp borders and a granular texture. VAIN may be multifocal, particularly in HIV-infected women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Vaginal cytology, colposcopy, and biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal and cervical cytology is performed, if these samples have not yet been obtained. Colposcopy is usually needed to visualize vaginal lesions. Biopsy is performed of all lesions that are suspicious for neoplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=see_link&amp;anchor=H16#H16\">",
"     \"Colposcopy\", section on 'Vaginal colposcopy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5560?source=see_link&amp;anchor=H8#H8\">",
"     \"Vaginal intraepithelial neoplasia\", section on 'Biopsy technique'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of HIV-infected women with of vulvar or vaginal intraepithelial neoplasia (VIN or VAIN) involves treatment of lesions as well as of the underlying HIV infection.",
"   </p>",
"   <p>",
"    Aspects of treatment for VIN and VAIN that are specific to women with HIV infection are described here. General principles of VIN and VAIN treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=see_link&amp;anchor=H12#H12\">",
"     \"Vulvar intraepithelial neoplasia\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5560?source=see_link&amp;anchor=H10#H10\">",
"     \"Vaginal intraepithelial neoplasia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Vulvar neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conservative surgical excision and destruction of the lesions are the mainstays of therapy for VIN in HIV-infected women, as they are in the general population. Total or even simple vulvectomy may be debilitating, particularly in immunosuppressed individuals, and is rarely required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=see_link&amp;anchor=H12#H12\">",
"     \"Vulvar intraepithelial neoplasia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Medical therapy of VIN is reserved for patients in whom excision with negative margins would necessitate significant vulvar mutilation (eg, clitoral, periurethral or perianal lesions). There are few data regarding medical therapy for VIN (eg, 5-fluorouracil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    , alpha-interferon, retinoids) in HIV-infected women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6455/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Women who fail treatment with topical therapy should be treated with surgical excision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Vaginal neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data regarding treatment of VAIN in HIV-infected women. The usual approach to treatment is the same as for the general population. Unifocal VAIN is treated with conservative surgical excision and destruction of the lesions. Multifocal or recurrent VAIN is best treated with topical 5-fluorouracil. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5560?source=see_link&amp;anchor=H10#H10\">",
"     \"Vaginal intraepithelial neoplasia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Highly active antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Highly active antiretroviral therapy (HAART) appears to decrease the incidence and recurrence of VIN [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6455/abstract/10,14\">",
"     10,14",
"    </a>",
"    ]. The magnitude of this effect was illustrated in a multicenter prospective study of 1562 HIV-positive women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6455/abstract/14\">",
"     14",
"    </a>",
"    ]. Current or former use of HAART compared with no HAART use was associated with a one-third decrease in the incidence of VIN, which was statistically significant in a multivariate analysis that controlled for CD4 count and HIV RNA level. Based upon these data, we suggest HAART rather than no antiretroviral therapy for HIV-infected women who are candidates for antiretroviral therapy and who have VIN. There are few data regarding the effect of HAART on vulvar cancer in HIV-infected women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6455/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Theoretically, HAART use should also decrease the incidence of VAIN and vaginal cancer, but no studies have investigated this question. Since a beneficial effect is seen for VIN and cervical intraepithelial neoplasia, which have the same HPV-mediated pathophysiology as VAIN. As a result, we suggest use of HAART for HIV-infected women with VAIN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18665?source=see_link&amp;anchor=H11#H11\">",
"     \"Preinvasive and invasive cervical neoplasia in HIV-infected women\", section on 'Highly active antiretroviral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information on the outcome of VIN and VAIN in HIV-infected women is limited. In the general population, the risk of recurrence after treatment of VIN and VAIN ranges from 20 to 70 percent and the risk of progression to invasive cancer ranges from 1 to 5 percent. The risk of recurrence of",
"    <span class=\"nowrap\">",
"     VIN/VAIN",
"    </span>",
"    appears to be higher in HIV-infected women than in other women, as it is for cervical intraepithelial neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6455/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. As an example, in a study of women with anogenital lesions, the recurrence rate after laser treatment was higher for patients with HIV compared with patients without HIV infection (26 versus 17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6455/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=see_link&amp;anchor=H23#H23\">",
"     \"Vulvar intraepithelial neoplasia\", section on 'Prognosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5560?source=see_link&amp;anchor=H9#H9\">",
"     \"Vaginal intraepithelial neoplasia\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with human immunodeficiency virus (HIV) infection are at an increased risk of vulvar and vaginal neoplasia. The incidence and severity of vulvar and vaginal neoplasia appears to be correlated with worsening immunosuppression. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Incidence'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For HIV-infected women, we suggest HPV vaccination (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Either the quadrivalent (HPV types 6, 11, 16, 18) or bivalent (HPV types 16 and 18) formulation can be used, but the quadrivalent vaccine offers the additional potential benefit of prevention of anogenital warts. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most women with vulvar intraepithelial neoplasia (VIN) or vaginal intraepithelial neoplasia (VAIN) are asymptomatic. In symptomatic women with VIN, the most common complaint is vulvar pruritus. Women with VAIN occasionally present with postcoital spotting or vaginal discharge. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that HIV-infected women undergo a careful vulvar and vaginal examination whenever a complete pelvic examination is performed (eg, for cervical cancer screening). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For HIV-infected women with abnormal cervical cytology in whom a cervical lesion is not identified, we suggest that vaginal cytology and colposcopy be performed. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VIN and VAIN are histologic diagnoses made using vulvar or vaginal biopsy. Biopsy may be directed by gross visual examination of lesions or by examination under magnification with a colposcope or hand-held magnifying device. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected women with VIN or VAIN are treated the same as women in the general population. Conservative surgical excision and destruction of lesions are the mainstays of therapy. Topical therapy is reserved for patients with multifocal disease. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=see_link&amp;anchor=H12#H12\">",
"       \"Vulvar intraepithelial neoplasia\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5560?source=see_link&amp;anchor=H10#H10\">",
"       \"Vaginal intraepithelial neoplasia\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For HIV-infected women with VIN or VAIN, we suggest highly active antiretroviral therapy rather than no antiretroviral therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Highly active antiretroviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/1\">",
"      Maiman M, Fruchter RG, Serur E, et al. Human immunodeficiency virus infection and cervical neoplasia. Gynecol Oncol 1990; 38:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/2\">",
"      Clark RA, Brandon W, Dumestre J, Pindaro C. Clinical manifestations of infection with the human immunodeficiency virus in women in Louisiana. Clin Infect Dis 1993; 17:165.",
"     </a>",
"    </li>",
"    <li>",
"     Robinson WR, Morris CB. Cervical Neoplasia: Pathogenesis, Diagnosis, and Management. In: Hematologic and Oncologic Aspects of HIV Infection - Hematology/Oncology Clinics of North America, Krown SE, Von Roenn JH (Eds), WB Saunders, Philadelphia 1996. Vol 10, p.1163.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/4\">",
"      Korn AP, Abercrombie PD, Foster A. Vulvar intraepithelial neoplasia in women infected with human immunodeficiency virus-1. Gynecol Oncol 1996; 61:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/5\">",
"      Chiasson MA, Ellerbrock TV, Bush TJ, et al. Increased prevalence of vulvovaginal condyloma and vulvar intraepithelial neoplasia in women infected with the human immunodeficiency virus. Obstet Gynecol 1997; 89:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/6\">",
"      Spitzer M. Lower genital tract intraepithelial neoplasia in HIV-infected women: guidelines for evaluation and management. Obstet Gynecol Surv 1999; 54:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/7\">",
"      Sch&auml;fer A, Friedmann W, Mielke M, et al. The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am J Obstet Gynecol 1991; 164:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/8\">",
"      Robinson WR, Barnes SE, Adams S, Perrin MS. Histology/cytology discrepancies in HIV-infected obstetric patients with normal pap smears. Gynecol Oncol 1997; 65:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/9\">",
"      Maiman M, Fruchter RG, Clark M, et al. Cervical cancer as an AIDS-defining illness. Obstet Gynecol 1997; 89:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/10\">",
"      Dedes KJ, Beneder C, Samartzis N, et al. Outcome of treated anogenital intraepithelial neoplasia among human immunodeficiency virus-infected women. J Reprod Med 2008; 53:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/11\">",
"      Sideri M, Jones RW, Wilkinson EJ, et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med 2005; 50:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/12\">",
"      Conley LJ, Ellerbrock TV, Bush TJ, et al. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002; 359:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/13\">",
"      Jamieson DJ, Paramsothy P, Cu-Uvin S, et al. Vulvar, vaginal, and perianal intraepithelial neoplasia in women with or at risk for human immunodeficiency virus. Obstet Gynecol 2006; 107:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/14\">",
"      Massad LS, Silverberg MJ, Springer G, et al. Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virus. Am J Obstet Gynecol 2004; 190:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/15\">",
"      Massad LS, Xie X, Greenblatt RM, et al. Effect of human immunodeficiency virus infection on the prevalence and incidence of vaginal intraepithelial neoplasia. Obstet Gynecol 2012; 119:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/16\">",
"      Huh WK. Human papillomavirus infection: a concise review of natural history. Obstet Gynecol 2009; 114:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/17\">",
"      Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009; 101:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/18\">",
"      Brown JE, Sunborg MJ, Kost E, et al. Vulvar cancer in human immunodeficiency virus-seropositive premenopausal women: a case series and review of the literature. J Low Genit Tract Dis 2005; 9:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/19\">",
"      Taube JM, Nichols AD, Bornman LS, et al. Langerhans cell density and high-grade vulvar intraepithelial neoplasia in women with human immunodeficiency virus infection. J Cutan Pathol 2007; 34:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/20\">",
"      Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/21\">",
"      Palefsky J. Human papillomavirus infection in HIV-infected persons. Top HIV Med 2007; 15:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/22\">",
"      Del Priore G, Herron MM. Retinoids for vulvar dysplasia in the HIV-infected patient. Int J Gynaecol Obstet 1996; 55:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/23\">",
"      Wendling J, Saiag P, Berville-Levy S, et al. Treatment of undifferentiated vulvar intraepithelial neoplasia with 5% imiquimod cream: a prospective study of 12 cases. Arch Dermatol 2004; 140:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/24\">",
"      Ahr A, Rody A, Kissler S, et al. [Risk factors for recurrence of vulvar intraepithelial neoplasia III (VIN III)]. Zentralbl Gynakol 2006; 128:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6455/abstract/25\">",
"      Aynaud O, Buffet M, Roman P, et al. Study of persistence and recurrence rates in 106 patients with condyloma and intraepithelial neoplasia after CO2 laser treatment. Eur J Dermatol 2008; 18:153.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3228 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-7705E05A5A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_19_6455=[""].join("\n");
var outline_f6_19_6455=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Vulvar neoplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Vulvar examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Vulvar colposcopy and biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vaginal neoplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Vaginal examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Vaginal cytology, colposcopy, and biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Vulvar neoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Vaginal neoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Highly active antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=related_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13480?source=related_link\">",
"      Clinical trials of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=related_link\">",
"      Colposcopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=related_link\">",
"      Condylomata acuminata (anogenital warts)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37349?source=related_link\">",
"      Diagnostic evaluation of vulvar lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20618?source=related_link\">",
"      Differential diagnosis of vulvar lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=related_link\">",
"      Epidemiology of human papillomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11670?source=related_link\">",
"      Evaluation of the HIV-infected patient with anorectal symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18665?source=related_link\">",
"      Preinvasive and invasive cervical neoplasia in HIV-infected women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36934?source=related_link\">",
"      Screening for cervical cancer in HIV infected women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5560?source=related_link\">",
"      Vaginal intraepithelial neoplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=related_link\">",
"      Vulvar intraepithelial neoplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_19_6456="Liver microcirculation";
var content_f6_19_6456=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Microcirculation of the liver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 558px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagram depicting the hepatic acinus and lobule. The \"lobule\" model considers the terminal hepatic venules to be the center of the hepatic microcirculation while the \"acinar\" model (also known as the Rappaport classification) considers it to represent the periphery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_19_6456=[""].join("\n");
var outline_f6_19_6456=null;
var title_f6_19_6457="Treatment of prosthetic joint infections";
var content_f6_19_6457=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of prosthetic joint infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/19/6457/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/19/6457/contributors\">",
"     Elie Berbari, MD, FIDSA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/19/6457/contributors\">",
"     Larry M Baddour, MD, FIDSA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/19/6457/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/19/6457/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/19/6457/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/19/6457/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/19/6457/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periprosthetic joint infection occurs in 1 to 2 percent of joint replacement surgeries and is one of the leading causes of arthroplasty failure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The issues relating to the medical and surgical treatment of prosthetic joint infections (PJIs) will be reviewed here. Infections associated with other implanted orthopedic devices, such as pins and rods, will not be specifically discussed, but similar principles apply [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biofilms play an important role in the pathogenesis of PJIs. Organisms within biofilm become resistant to therapy; as a result, antimicrobial therapy is often unsuccessful unless the biofilm is physically disrupted or removed by surgical debridement. Biofilms also account for two other features of PJIs: the propensity of infection to become apparent weeks or months after surgery, and the common observation that antimicrobial therapy results in a clinical response that is typically followed by a relapse within days or months if the infected prosthesis is retained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42680?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and diagnosis of prosthetic joint infections\", section on 'Biofilm'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis, clinical manifestations, and prevention of these infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42680?source=see_link\">",
"     \"Clinical manifestations and diagnosis of prosthetic joint infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28198?source=see_link\">",
"     \"Prevention of prosthetic joint infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TIMING OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prosthetic joint infections (PJIs) are categorized according to the timing of symptom onset after implantation: early-onset (&lt;3 months after surgery), delayed-onset (from 3 to 12 months after surgery), and late-onset (&gt;12 months after surgery). These infections have the following characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early-onset infections are usually acquired during implantation and are often due to virulent organisms, such as S. aureus, gram-negative bacilli, anaerobic organisms, or mixed infections [",
"      <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/1,4\">",
"       1,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Delayed-onset infections are also usually acquired during implantation. Consistent with the indolent presentation, delayed infections are usually caused by less virulent organisms, such as coagulase-negative staphylococci (CoNS) or enterococci.",
"     </li>",
"     <li>",
"      Late-onset infections typically result from hematogenous seeding. S. aureus, beta hemolytic streptococci, and Enterobacteriaceae are responsible for most infections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These definitions reflect the microbiology and pathophysiology of PJI, but should not be used for decisions regarding whether a prosthesis can be retained or should be removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8190615\">",
"    <span class=\"h1\">",
"     CLINICAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of prosthetic joint infections (PJIs) generally involves both surgery and antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/5\">",
"     5",
"    </a>",
"    ]. The type of surgery and antibiotic regimen depends on the timeframe of infection, the etiologic organism, and other individual patient circumstances. Surgical options include replacement arthroplasty (in one or two stages), debridement and retention of prosthesis, or resection arthroplasty in the absence of hardware reimplantation. In the United States, two-stage replacement arthroplasty is the most common surgical approach for management of PJI.",
"   </p>",
"   <p>",
"    The choice and duration of antibiotic therapy for treatment of PJI must be tailored to surgical management as described in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15429516\">",
"    <span class=\"h2\">",
"     Replacement arthroplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of delayed-onset and late-onset infections require prosthesis removal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/6\">",
"     6",
"    </a>",
"    ]. Options for replacement arthroplasty in patients with PJIs include one-stage or two-stage procedures. The two-stage procedure is associated with the highest success rates and is the preferred procedure in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]; the one-stage procedure is more commonly performed in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibiotic impregnated cement spacers are commonly used in between stages [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Data are insufficient to determine whether use of antibiotic impregnated cement in temporary spacers confers additional benefit for treatment of PJI beyond the benefit associated with systemic antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Therefore the optimal approach to their use is uncertain; further study is needed.",
"   </p>",
"   <p>",
"    Cemented reimplants are frequently fixed using cement impregnated with antimicrobial agents; the efficacy of this approach is uncertain. Most commercially available antibiotic impregnated cements are prepared with aminoglycosides, which are appropriate for infection due to gram-negative organisms. In the setting of infection due to gram-positive organisms, it may be appropriate to mix",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    with a commercial preparation containing an aminoglycoside.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15429531\">",
"    <span class=\"h3\">",
"     Two-stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;A two-stage strategy is the most common surgical procedure performed in the United States for management of PJI. This procedure consists of prosthesis resection, debridement of soft tissue and bone, and placement of a joint spacer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Following removal of the infected prosthesis, parenteral antibiotics with activity against the infecting organism(s) are administered for four to six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/9\">",
"     9",
"    </a>",
"    ]. Reimplantation of a new prosthesis is done following completion of antibiotic therapy.",
"   </p>",
"   <p>",
"    The use of an antimicrobial impregnated joint spacer for local delivery of antimicrobial therapy is a standard practice for two-stage surgery to manage PJI [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/9\">",
"     9",
"    </a>",
"    ]. An articulating or static (non-articulating) spacer may be used. Use of an articulating spacer may permit earlier ambulation, while use of a static spacer may limit range of motion and lead to muscle atrophy and arthrofibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many experts favor an observation period of two or more weeks off any prior antibiotics in prior to implantation of a new prosthesis, with repeat culture to assess sterilization of the joint space; others favor proceeding directly with implantation of a new prosthesis following completion of antibiotics if there are no clinical signs of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]. A longer duration between stages to ascertain the lack of recurrent infection should be weighed against the potential for joint arthrofibrosis and diminished functional outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/9\">",
"     9",
"    </a>",
"    ]. Obtaining specimens for culture and histopathology prior to reimplantation may be most useful in cases of infection due to difficult-to-treat organisms such as methicillin-resistant staphylococci, Pseudomonas species, or enterococci.",
"   </p>",
"   <p>",
"    The role of culture prior to reimplantation was evaluated in a prospective study including 69 patients with knee arthroplasty infection managed with two-stage replacement arthroplasty; half had joint replacement immediately after completing six weeks of antimicrobial therapy, while the other half had repeat culture four weeks after completion of antimicrobial therapy prior to joint replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/18\">",
"     18",
"    </a>",
"    ]. Those with positive cultures underwent repeat debridement and a repeat course of antibiotic therapy prior to joint replacement; those with negative cultures underwent prompt joint replacement. The rate of recurrent infection was lower among the patients who underwent culture prior to reimplantation than those who did not (3 versus 14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/18\">",
"     18",
"    </a>",
"    ]. In contrast, another study including 152 patients with PJI noted that the presence of positive cultures obtained at the time of new prosthesis implantation was not associated with a worse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A persistently elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) at the time of reimplantation surgery may or may not be accurate in predicting the presence of persistent PJI. In one study of 76 patients treated with two-stage exchange, ESR remained persistently elevated in 37 (54 percent), and CRP remained elevated in 14 (21 percent) patients, without any evidence of residual infection at the time of reimplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/20\">",
"     20",
"    </a>",
"    ]. The need for subsequent debridement prior to reimplantation must be interpreted in the context of the entire clinical picture when deciding timing of reimplantation. Routine synovial fluid examination and joint aspirate cultures prior to reimplantation is not required, but can be pursued in selected cases when there is clinical concern regarding the presence of persistent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approach to systemic antibiotic therapy following reimplantation of a new prosthesis depends on culture data obtained at the time of reimplantation as well as previous culture data obtained at the time of the original resection. It is reasonable to institute empiric antibiotic therapy pending availability of culture data, which can be discontinued if cultures are negative. Patients with positive cultures should be managed as outlined above for one-stage replacement arthroplasty. (See",
"    <a class=\"local\" href=\"#H4163000\">",
"     'One-stage'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The success rate of two-stage exchange arthroplasty is close to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/8,18,21,22\">",
"     8,18,21,22",
"    </a>",
"    ], although most studies excluded patients who had a permanent resection arthroplasty without a second-stage reimplantation, usually due to persistent infection in the joint or periarticular tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/8,18,23\">",
"     8,18,23",
"    </a>",
"    ]. In addition, the published duration of follow-up has varied widely; therefore, it is difficult to use published success rates to predict the outcome in individual patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4163000\">",
"    <span class=\"h3\">",
"     One-stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;A one-stage (also called direct exchange) procedure consists of prosthesis resection, debridement of the soft tissue and bone, and reimplantation of new hardware during the same surgery. This procedure may be used in patients with a total hip arthroplasty infection who have a good soft tissue envelope and an easily treatable microorganism. In selected case series, the success rate of this procedure approaches 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/24\">",
"     24",
"    </a>",
"    ]. Given the lack of comparative effectiveness trials, it is difficult to recommend this procedure over the two-stage approach [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/25-29\">",
"     25-29",
"    </a>",
"    ]. Based on published literature, a one-stage approach may be suitable in highly selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial therapy for treatment of S. aureus infection following one-stage replacement arthroplasty consists of four to six weeks of pathogen-specific intravenous therapy in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (300 to 450 mg orally twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/9\">",
"     9",
"    </a>",
"    ]. Subsequent therapy consists of three months of pathogen-specific oral therapy in combination with rifampin. Options for oral therapy include fluoroquinolones,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/11/3253?source=see_link\">",
"     dicloxacillin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Initial therapy for treatment following one-stage replacement arthroplasty for organisms other than S. aureus consists of four to six weeks of pathogen-specific intravenous or highly bioavailable oral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following initial antibiotic therapy for one-stage replacement arthroplasty, indefinite antibiotic suppression with an oral agent may be warranted; determination regarding the use of suppressive therapy depends on individual patient circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/9\">",
"     9",
"    </a>",
"    ]. Factors favoring use of indefinite suppression include lack of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    during the initial phase of treatment (if S. aureus infection was present)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    moderate likelihood for progressive implant loosening",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    loss of bone stock; factors against use of indefinite suppression include adverse effects related to prolonged antibiotic therapy.",
"   </p>",
"   <p>",
"    Thereafter, indefinite antibiotic suppression with an oral agent may be warranted; determination regarding the use of suppressive therapy depends on individual patient circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4162571\">",
"    <span class=\"h2\">",
"     Debridement and retention of prosthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical circumstances for which debridement, polyethylene liner exchange, and retention of prosthesis may be an appropriate strategy include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early-onset PJI (eg, within approximately 30 days of prosthesis implantation or &lt;3 weeks of symptom onset) in the setting of a well-fixed prosthesis without a sinus tract [",
"      <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/9\">",
"       9",
"      </a>",
"      ]. Surgical debridement followed by a long course of parenteral antibiotics is curative in up to 71 percent of early-onset infections [",
"      <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/31-33\">",
"       31-33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients for whom alternative surgical strategies are not acceptable because of high risk may also be considered for a debridement and retention strategy; in such cases, the likelihood of relapsed infection is greater than for patients who undergo replacement arthroplasty [",
"      <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/9,34\">",
"       9,34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Debridement alone is insufficient treatment of PJI if the prosthesis is loose; in such cases, replacement arthroplasty is required.",
"   </p>",
"   <p>",
"    The choice and duration of antimicrobial therapy in the setting of prosthesis debridement and retention depend on the identification of the infecting organism as well as individual patient circumstances, including the duration of infection, the stability of the prosthesis, and concomitant medical conditions.",
"   </p>",
"   <p>",
"    Initial therapy for treatment of staphylococcal infection of a retained prosthetic joint consists of four to six weeks of pathogen-specific intravenous therapy in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (300 to 450 mg orally twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/9,33\">",
"     9,33",
"    </a>",
"    ]. Subsequent therapy for management of hip, elbow, shoulder, or ankle PJI consists of three months of pathogen-specific oral therapy in combination with rifampin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/4,32,33,35-37\">",
"     4,32,33,35-37",
"    </a>",
"    ]. Subsequent therapy for management of knee PJI consists of six months of pathogen-specific oral therapy in combination with rifampin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/9,23\">",
"     9,23",
"    </a>",
"    ]. Options for oral therapy include fluoroquinolones,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/11/3253?source=see_link\">",
"     dicloxacillin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    is useful in the setting of staphylococcal PJI because it is capable of penetrating biofilm. Rifampin has significant drug interactions and risk of toxicity in patients with preexisting liver disease; careful consideration of an individual's other medications and medical history (particularly history of liver disease) is required prior to initiation of rifampin. The success rate in the absence of rifampin for cases of prosthesis retention in staphylococcal PJI is typically 50 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/8,24,38-40\">",
"     8,24,38-40",
"    </a>",
"    ]. Risk factors independently associated with treatment failure include the presence of a sinus tract and symptom duration of 21 days or more prior to debridement [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial therapy for treatment of retained PJI due to organisms other than S. aureus consists of four to six weeks of pathogen-specific intravenous or oral therapy that has high bioavailability [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/9\">",
"     9",
"    </a>",
"    ]. Following initial antibiotic therapy for retained PJI, indefinite antibiotic suppression with an oral agent may be warranted; determination regarding the use of suppressive therapy depends on individual patient circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/9\">",
"     9",
"    </a>",
"    ]. Factors favoring use of indefinite suppression include lack of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    use during the initial phase of treatment (if S. aureus infection was present)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    moderate likelihood for progressive implant loosening",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    loss of bone stock; factors against use of indefinite suppression include adverse effects related to prolonged antibiotic therapy. Suppressive oral antibiotic therapy typically postpones rather than prevents treatment failure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/19,31,40\">",
"     19,31,40",
"    </a>",
"    ]. Some patients on suppressive therapy eventually develop septic loosening of the prosthesis; a minority develops frank purulence in the joint space or sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3815404\">",
"    <span class=\"h2\">",
"     Permanent resection arthroplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management options are limited for patients with PJI who are functionally impaired, have significant medical or surgical comorbidities, have poor bone stock or soft tissue coverage, or cannot undergo a prolonged course of appropriate antimicrobial therapy.",
"   </p>",
"   <p>",
"    In these situations, patients with total hip arthroplasty infection may undergo permanent resection arthroplasty without arthrodesis (Girdlestone procedure). Patients with total knee arthroplasty infection may undergo permanent resection with arthrodesis. If hardware resection is not possible, long-term antimicrobial suppression may be warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arthrodesis may be a reasonable approach for patients who are unable to undergo reimplantation arthroplasty. The surgical approach depends on individual circumstances. In some cases, external fixation devices or placement of an internal fixator, such as a long arthrodesis nail, may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/42\">",
"     42",
"    </a>",
"    ]. When successful, this procedure usually provides reasonable pain relief, although there may be significant functional drawbacks such as leg length discrepancy and difficulty walking.",
"   </p>",
"   <p>",
"    Following permanent prosthesis explantation, a four- to six-week course of pathogen directed parenteral antibiotic therapy or highly oral bioavailable agent should be administered [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arthrodesis may be difficult to perform in patients with extensive osteomyelitis, osteolysis, or extensive loss of cancellous or cortical bone. In such cases, amputation may be the only alternative. Factors leading to amputation include severe bone loss, intractable pain, and multiple failed revision attempts [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CHOICE OF ANTIBIOTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of antibiotic therapy in patients with prosthetic joint infections (PJIs) is to cure or control the infectious process. There is a paucity of randomized controlled trials that have the efficacy of antibiotic therapy in patients with PJIs. The literature on this issue consists almost exclusively of retrospective case series in which widely different regimens and durations of therapy are reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Empiric antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, it is preferable to delay antibiotic therapy until specimens for culture are obtained by joint aspiration, joint debridement,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prosthesis removal. In rare cases, administration of empiric antibiotic therapy may be justified for patients with PJI who present with sepsis or are otherwise too unstable to wait for culture data to guide therapy. In such cases, empiric antimicrobial therapy should include coverage against staphylococci (including methicillin resistant strains) and aerobic gram-negative bacilli (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ). Subsequently, antibiotic therapy should adjusted to culture and in-vitro susceptibility data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pathogen-specific antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients treated with one- or two-stage surgery, debridement surgery, or resection arthroplasty without delayed reimplantation require a four- to six-week course of parenteral antimicrobial therapy following surgery. In patients treated with debridement and retention, parenteral antimicrobial therapy is typically followed by a long-term course of oral antimicrobial therapy when possible, the duration of which varies and is dependent on several factors (as outlined below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Staphylococci",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     Nafcillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    (2 g intravenously every four to six hours) is the most effective therapy against methicillin-sensitive S. aureus (MSSA).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     Cefazolin",
"    </a>",
"    (1 to 2 g intravenously every eight hours) may be used as an alternative agent. Retrospective data suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g intravenously every 24 hours) may be as effective as other antistaphylococcal beta-lactams for treatment of oxacillin susceptible staphylococcal PJIs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/19,45\">",
"     19,45",
"    </a>",
"    ]. For outpatient antimicrobial therapy in hospitalized patients started on an antistaphylococcal semi-synthetic penicillin (such as methicillin, nafcillin, or oxacillin), treatment can be continued via infusion pump; alternatively, administration of a cephalosporin with less frequent dosing may allow greater convenience. Patients a history of type I allergy (anaphylaxis) to penicillin can be treated with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (900 mg intravenously every eight hours) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily intravenously in two divided doses to a maximum dose of 2",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"   </p>",
"   <p>",
"    Methicillin-resistant",
"    S. aureus (MRSA) infection should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/42/27301?source=see_link\">",
"     telavancin",
"    </a>",
"    can be used as alternative agents [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/35,46,47\">",
"     35,46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/47/15096?source=see_link\">",
"     \"Vancomycin dosing and serum concentration monitoring in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment regimens for CoNS are identical to those for S. aureus. However, most strains of CoNS that cause PJI are methicillin-resistant.",
"   </p>",
"   <p>",
"    Combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (300 to 450 mg orally twice daily) is used in the setting of staphylococcal PJI treated with debridement and retention of the prosthesis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in the setting of one-stage arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Streptococci (beta-hemolytic)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of choice for streptococcal PJI is penicillin (12 to 18 million",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    in four divided doses) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    (2 g every six hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/48\">",
"     48",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     Ceftriaxone",
"    </a>",
"    (1 to 2 g intravenously every 24 hours) is an equally acceptable agent and is favored for dosing convenience in the outpatient setting. Patients allergic to penicillin may be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (900 mg intravenously every eight hours) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily intravenously in two divided doses to a maximum dose of 4",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    outcome of PJI due to penicillin-susceptible streptococci treated with debridement and prolonged antibiotic therapy is generally good. In one retrospective series, the cumulative risk of relapse in patients who underwent debridement early after onset of symptoms was 11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Enterococci",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enterococcal PJIs are rare, and it can be difficult to distinguish between true infection and culture contamination. If cultures demonstrating enterococcus are felt to represent true infection, selection of antibiotic therapy should be tailored to susceptibility results (",
"    <a class=\"graphic graphic_table graphicRef71921 \" href=\"UTD.htm?12/37/12892\">",
"     table 1",
"    </a>",
"    ). In a retrospective review of 47 patients, there was no difference in outcome between patients receiving combination and those receiving monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=see_link\">",
"     \"Treatment of enterococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Gram-negative bacilli",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gram-negative bacilli cause 15 percent of all first-time episodes of PJIs. Patients with gram-negative infections tended to be older, to develop infections earlier after surgery, and may have worse outcomes with prolonged antibiotic therapy and debridement than patients with PJI due to gram-positive organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/6,50\">",
"     6,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gram-negative bacilli that are susceptible to fluoroquinolones can usually be treated orally with an agent, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (500 to 750 mg twice daily). PJIs due to P. aeruginosa are difficult to cure even with debridement and prosthesis removal. One of the following regimens may be used [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       Cefepime",
"      </a>",
"      2 g intravenously every 12 hours (preferred)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       Meropenem",
"      </a>",
"      1 g intravenously every 8 hours (preferred)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      750 mg orally every 12 hours (alternative)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       Ceftazidime",
"      </a>",
"      2 g intravenously every 8 hours (alternative)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Anaerobes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prosthetic hip or knee infections due to anaerobes are relatively uncommon; shoulder infections due to Propionibacterium acnes are the most common presentation of anaerobic PJI. Options for treatment of infection due to Propionibacterium acnes include penicillin (24 million units intravenously every 24 hours given in six equally divided doses or as continuous infusion) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (1 to 2 g intravenously once daily).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    are also active against most Propionibacterium acnes isolates.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    (500 mg orally three times a day) may be used for other types of anaerobic infections that are susceptible to this agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43383?source=see_link\">",
"     \"Invasive Propionibacterium infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Mycobacterium tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;PJIs due to M. tuberculosis can sometimes be cured without joint removal if the infection is recognized early [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=see_link\">",
"     \"Skeletal tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Fungi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of fungal PJIs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11671?source=see_link\">",
"     \"Candida osteoarticular infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Culture negative",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small proportion of patients with PJIs have negative cultures. In a review of 897 episodes of PJIs, 7 percent of patients had culture-negative PJI; about one-half of these patients had received prior antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with culture-negative PJIs should receive antimicrobial agents with activity against gram-positive and gram-negative pathogens. Suggested regimens include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    with ciprofloxacin at doses outlined above.",
"   </p>",
"   <p>",
"    Patients with culture negative PJI have similar outcomes as patients with positive cultures following standard treatment regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/19,52\">",
"     19,52",
"    </a>",
"    ]. In one retrospective study including 60 patients with PJI and negative cultures, five-year survival free of treatment failure was 94 percent in patients treated with two-stage exchange arthroplasties and 71 percent in patients who underwent debridement with retention of their prosthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective analysis of 200 episodes of prosthetic joint infection (PJI) in patients with rheumatoid arthritis between January 1969 and December 1995 assessed rates of five-year survival free of treatment failure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/39\">",
"     39",
"    </a>",
"    ]. In multivariate analysis, the type of surgical procedure was the only variable that was associated with treatment failure. The rates of five-year survival free of treatment failure were by surgical procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Two-stage exchange &ndash; 79 percent (95% CI 66-93)",
"     </li>",
"     <li>",
"      Resection arthroplasty &ndash; 61 percent (95% CI 49-74)",
"     </li>",
"     <li>",
"      Debridement with retention of components &ndash; 32 percent (95% CI 21-49)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limitations included issues to the retrospective nature of the study (eg, no established treatment protocol, no randomization, inability to assess all potential variables) and the differences in surgical modalities used over the 27 years covered by the analysis.",
"   </p>",
"   <p>",
"    In one large multicenter study of 345 episodes of S. aureus PJI managed with implant retention, a success rate of 55 percent was reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/53\">",
"     53",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    -based combinations exhibited an independent effect on enhancing success.",
"   </p>",
"   <p>",
"    Risk factors that predispose to treatment failure were identified in a retrospective study of 99 episodes of PJI in patients treated with debridement and retention of components [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/40\">",
"     40",
"    </a>",
"    ]. The median duration of intravenous antimicrobial therapy was 28 days followed by oral suppression for a median duration of 541 days. The two-year survival rate free of treatment failure was 60 percent. A multivariable analysis identified the presence of a sinus tract (hazard ratio [HR], 2.84; 95% CI 1.48-5.44) and a duration of symptoms prior to debridement of &ge;8 days (HR 1.77; 95% CI 1.02-3.07) as associated with an increased risk of treatment failure. In addition, outcomes for methicillin-resistant S. aureus (MRSA) PJIs are often poor, with treatment failure rates as high as 38 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/19/6457/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/50/29474?source=see_link\">",
"       \"Patient information: Knee replacement (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/34/23075?source=see_link\">",
"       \"Patient information: Hip replacement (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/21/18769?source=see_link\">",
"       \"Patient information: Joint infection (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=see_link\">",
"       \"Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/13/21717?source=see_link\">",
"       \"Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of prosthetic joint infections (PJIs) involves both surgery and antibiotic therapy. The type of surgery and the antibiotic regimen depend on the timing of infection, the etiologic organism and other individual patient circumstances. (See",
"      <a class=\"local\" href=\"#H8190615\">",
"       'Clinical approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of delayed-onset and late-onset infections require replacement arthroplasty; two-stage procedures are associated with highest success rates and are the most common procedures performed in the United States. (See",
"      <a class=\"local\" href=\"#H15429516\">",
"       'Replacement arthroplasty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A two-stage replacement arthroplasty procedure consists of prosthesis resection, debridement of soft tissue and bone, and placement of a spacer. Subsequently, a prolonged course of antibiotics is administered, after which new hardware is implanted. Some favor proceeding directly with implantation of a new prosthesis following completion of antibiotics if there are no clinical signs of infection, while others favor an observation period of two to eight weeks off of antibiotics prior to implantation of a new prosthesis, with repeat culture to assess sterilization of the joint space. (See",
"      <a class=\"local\" href=\"#H15429531\">",
"       'Two-stage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A one-stage replacement arthroplasty procedure consists of prosthesis resection, debridement of soft tissue and bone, and reimplantation of new hardware during the same surgery. Antibiotic management for one-stage arthroplasty consists of prolonged initial therapy, followed by antibiotic suppression in some cases. (See",
"      <a class=\"local\" href=\"#H4163000\">",
"       'One-stage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Debridement and retention of prosthesis may be appropriate in the setting of early-onset PJI,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      for patients who cannot undergo alternative surgical management. Antibiotic therapy consists of prolonged initial therapy followed by antibiotic suppression in some cases. (See",
"      <a class=\"local\" href=\"#H4162571\">",
"       'Debridement and retention of prosthesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The approach to selection of antibiotic therapy depends on culture and susceptibility data. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Choice of antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/1\">",
"      Widmer AF. New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis 2001; 33 Suppl 2:S94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/2\">",
"      Berbari EF, Hanssen AD, Duffy MC, et al. Risk factors for prosthetic joint infection: case-control study. Clin Infect Dis 1998; 27:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/3\">",
"      Sperling JW, Kozak TK, Hanssen AD, Cofield RH. Infection after shoulder arthroplasty. Clin Orthop Relat Res 2001; :206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/4\">",
"      Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004; 351:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/5\">",
"      Lentino JR. Prosthetic joint infections: bane of orthopedists, challenge for infectious disease specialists. Clin Infect Dis 2003; 36:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/6\">",
"      Hsieh PH, Lee MS, Hsu KY, et al. Gram-negative prosthetic joint infections: risk factors and outcome of treatment. Clin Infect Dis 2009; 49:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/7\">",
"      Wilde AH. Management of infected knee and hip prostheses. Curr Opin Rheumatol 1994; 6:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/8\">",
"      Brandt CM, Duffy MC, Berbari EF, et al. Staphylococcus aureus prosthetic joint infection treated with prosthesis removal and delayed reimplantation arthroplasty. Mayo Clin Proc 1999; 74:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/9\">",
"      Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the infectious diseases society of america. Clin Infect Dis 2013; 56:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/10\">",
"      Hanssen AD, Spangehl MJ. Practical applications of antibiotic-loaded bone cement for treatment of infected joint replacements. Clin Orthop Relat Res 2004; :79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/11\">",
"      Nelson CL. The current status of material used for depot delivery of drugs. Clin Orthop Relat Res 2004; :72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/12\">",
"      Jacobs C, Christensen CP, Berend ME. Static and mobile antibiotic-impregnated cement spacers for the management of prosthetic joint infection. J Am Acad Orthop Surg 2009; 17:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/13\">",
"      Parvizi J, Saleh KJ, Ragland PS, et al. Efficacy of antibiotic-impregnated cement in total hip replacement. Acta Orthop 2008; 79:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/14\">",
"      Iarikov D, Demian H, Rubin D, et al. Choice and doses of antibacterial agents for cement spacers in treatment of prosthetic joint infections: review of published studies. Clin Infect Dis 2012; 55:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/15\">",
"      Biring GS, Kostamo T, Garbuz DS, et al. Two-stage revision arthroplasty of the hip for infection using an interim articulated Prostalac hip spacer: a 10- to 15-year follow-up study. J Bone Joint Surg Br 2009; 91:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/16\">",
"      Cui Q, Mihalko WM, Shields JS, et al. Antibiotic-impregnated cement spacers for the treatment of infection associated with total hip or knee arthroplasty. J Bone Joint Surg Am 2007; 89:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/17\">",
"      Mittal Y, Fehring TK, Hanssen A, et al. Two-stage reimplantation for periprosthetic knee infection involving resistant organisms. J Bone Joint Surg Am 2007; 89:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/18\">",
"      Mont MA, Waldman BJ, Hungerford DS. Evaluation of preoperative cultures before second-stage reimplantation of a total knee prosthesis complicated by infection. A comparison-group study. J Bone Joint Surg Am 2000; 82-A:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/19\">",
"      Bejon P, Berendt A, Atkins BL, et al. Two-stage revision for prosthetic joint infection: predictors of outcome and the role of reimplantation microbiology. J Antimicrob Chemother 2010; 65:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/20\">",
"      Kusuma SK, Ward J, Jacofsky M, et al. What is the role of serological testing between stages of two-stage reconstruction of the infected prosthetic knee? Clin Orthop Relat Res 2011; 469:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/21\">",
"      Robbins GM, Masri BA, Garbuz DS, Duncan CP. Primary total hip arthroplasty after infection. Instr Course Lect 2001; 50:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/22\">",
"      Hsieh PH, Shih CH, Chang YH, et al. Two-stage revision hip arthroplasty for infection: comparison between the interim use of antibiotic-loaded cement beads and a spacer prosthesis. J Bone Joint Surg Am 2004; 86-A:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/23\">",
"      Waldman BJ, Hostin E, Mont MA, Hungerford DS. Infected total knee arthroplasty treated by arthroscopic irrigation and d&eacute;bridement. J Arthroplasty 2000; 15:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/24\">",
"      Sia IG, Berbari EF, Karchmer AW. Prosthetic joint infections. Infect Dis Clin North Am 2005; 19:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/25\">",
"      Raut VV, Siney PD, Wroblewski BM. One-stage revision of total hip arthroplasty for deep infection. Long-term followup. Clin Orthop Relat Res 1995; :202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/26\">",
"      Ure KJ, Amstutz HC, Nasser S, Schmalzried TP. Direct-exchange arthroplasty for the treatment of infection after total hip replacement. An average ten-year follow-up. J Bone Joint Surg Am 1998; 80:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/27\">",
"      Jackson WO, Schmalzried TP. Limited role of direct exchange arthroplasty in the treatment of infected total hip replacements. Clin Orthop Relat Res 2000; :101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/28\">",
"      Callaghan JJ, Katz RP, Johnston RC. One-stage revision surgery of the infected hip. A minimum 10-year followup study. Clin Orthop Relat Res 1999; :139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/29\">",
"      Hope PG, Kristinsson KG, Norman P, Elson RA. Deep infection of cemented total hip arthroplasties caused by coagulase-negative staphylococci. J Bone Joint Surg Br 1989; 71:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/30\">",
"      von Foerster G, Kl&uuml;ber D, K&auml;bler U. [Mid- to long-term results after treatment of 118 cases of periprosthetic infections after knee joint replacement using one-stage exchange surgery]. Orthopade 1991; 20:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/31\">",
"      Byren I, Bejon P, Atkins BL, et al. One hundred and twelve infected arthroplasties treated with 'DAIR' (debridement, antibiotics and implant retention): antibiotic duration and outcome. J Antimicrob Chemother 2009; 63:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/32\">",
"      Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998; 279:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/33\">",
"      El Helou OC, Berbari EF, Lahr BD, et al. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis 2010; 29:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/34\">",
"      Fisman DN, Reilly DT, Karchmer AW, Goldie SJ. Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly. Clin Infect Dis 2001; 32:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/35\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/36\">",
"      G&oacute;mez J, Canovas E, Ba&ntilde;os V, et al. Linezolid plus rifampin as a salvage therapy in prosthetic joint infections treated without removing the implant. Antimicrob Agents Chemother 2011; 55:4308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/37\">",
"      Nguyen S, Pasquet A, Legout L, et al. Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. Clin Microbiol Infect 2009; 15:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/38\">",
"      Deirmengian C, Greenbaum J, Lotke PA, et al. Limited success with open debridement and retention of components in the treatment of acute Staphylococcus aureus infections after total knee arthroplasty. J Arthroplasty 2003; 18:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/39\">",
"      Berbari EF, Osmon DR, Duffy MC, et al. Outcome of prosthetic joint infection in patients with rheumatoid arthritis: the impact of medical and surgical therapy in 200 episodes. Clin Infect Dis 2006; 42:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/40\">",
"      Marculescu CE, Berbari EF, Hanssen AD, et al. Outcome of prosthetic joint infections treated with debridement and retention of components. Clin Infect Dis 2006; 42:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/41\">",
"      Segreti J, Nelson JA, Trenholme GM. Prolonged suppressive antibiotic therapy for infected orthopedic prostheses. Clin Infect Dis 1998; 27:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/42\">",
"      J&oslash;rgensen PS, T&oslash;rholm C. Arthrodesis after infected knee arthroplasty using long arthrodesis nail. A report of five cases. Am J Knee Surg 1995; 8:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/43\">",
"      Salgado CD, Dash S, Cantey JR, Marculescu CE. Higher risk of failure of methicillin-resistant Staphylococcus aureus prosthetic joint infections. Clin Orthop Relat Res 2007; 461:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/44\">",
"      Isiklar ZU, Landon GC, Tullos HS. Amputation after failed total knee arthroplasty. Clin Orthop Relat Res 1994; :173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/45\">",
"      Tice AD, Hoaglund PA, Shoultz DA. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med 2003; 114:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/46\">",
"      Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/47\">",
"      Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/48\">",
"      Meehan AM, Osmon DR, Duffy MC, et al. Outcome of penicillin-susceptible streptococcal prosthetic joint infection treated with debridement and retention of the prosthesis. Clin Infect Dis 2003; 36:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/49\">",
"      El Helou OC, Berbari EF, Marculescu CE, et al. Outcome of enterococcal prosthetic joint infection: is combination systemic therapy superior to monotherapy? Clin Infect Dis 2008; 47:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/50\">",
"      Aboltins CA, Dowsey MM, Buising KL, et al. Gram-negative prosthetic joint infection treated with debridement, prosthesis retention and antibiotic regimens including a fluoroquinolone. Clin Microbiol Infect 2011; 17:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/51\">",
"      Spinner RJ, Sexton DJ, Goldner RD, Levin LS. Periprosthetic infections due to Mycobacterium tuberculosis in patients with no prior history of tuberculosis. J Arthroplasty 1996; 11:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/52\">",
"      Berbari EF, Marculescu C, Sia I, et al. Culture-negative prosthetic joint infection. Clin Infect Dis 2007; 45:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/19/6457/abstract/53\">",
"      Lora-Tamayo J, Murillo O, Iribarren JA, et al. A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis 2013; 56:182.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7665 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-1759BFA714-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_19_6457=[""].join("\n");
var outline_f6_19_6457=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TIMING OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8190615\">",
"      CLINICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15429516\">",
"      Replacement arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15429531\">",
"      - Two-stage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4163000\">",
"      - One-stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4162571\">",
"      Debridement and retention of prosthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3815404\">",
"      Permanent resection arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CHOICE OF ANTIBIOTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Empiric antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pathogen-specific antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Staphylococci",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Streptococci (beta-hemolytic)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Enterococci",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Gram-negative bacilli",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Anaerobes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Mycobacterium tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Fungi",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Culture negative",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7665\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7665|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/37/12892\" title=\"table 1\">",
"      Parenteral rx enterococci",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11671?source=related_link\">",
"      Candida osteoarticular infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42680?source=related_link\">",
"      Clinical manifestations and diagnosis of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43383?source=related_link\">",
"      Invasive Propionibacterium infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/34/23075?source=related_link\">",
"      Patient information: Hip replacement (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/21/18769?source=related_link\">",
"      Patient information: Joint infection (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/50/29474?source=related_link\">",
"      Patient information: Knee replacement (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=related_link\">",
"      Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/13/21717?source=related_link\">",
"      Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28198?source=related_link\">",
"      Prevention of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=related_link\">",
"      Skeletal tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=related_link\">",
"      Treatment of enterococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/47/15096?source=related_link\">",
"      Vancomycin dosing and serum concentration monitoring in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_19_6458="Normal breast histology";
var content_f6_19_6458=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F57619%7EENDO%2F62060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F57619%7EENDO%2F62060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal male breast tissue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal adult male breast tissue demonstrating a duct lined by a single layer of epithelial cells and surrounded by a loose stroma devoid of inflammatory infiltrate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn D Braunstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Florid stage of gynecomastia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histopathology of the florid stage of gynecomastia demonstrating the proliferation of ductal epithelium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Braunstein, GD, Hosp Pract 1993; 28:37.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal male breast tissue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal adult male breast tissue demonstrating a duct lined by a single layer of epithelial cells and surrounded by a loose stroma devoid of inflammatory infiltrate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn D Braunstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_19_6458=[""].join("\n");
var outline_f6_19_6458=null;
var title_f6_19_6459="Umbilical cord length";
var content_f6_19_6459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal umbilical cord length",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Gestation, weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Length, cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        32 +/- 9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        40 +/- 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        45 +/- 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        50 +/- 12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        56 +/- 13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        57 +/- 13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        60 +/- 13",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_19_6459=[""].join("\n");
var outline_f6_19_6459=null;
var title_f6_19_6460="RTV boosted PI regimens";
var content_f6_19_6460=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ritonavir-boosted protease inhibitor-based antiretroviral therapy in treatment-naive patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Protease inhibitor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Saquinavir",
"       </td>",
"       <td>",
"        SQV 400 mg bid + RTV 400 mg bid",
"       </td>",
"       <td>",
"        Used infrequently due to poor GI tolerance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SQV 1000 mg bid + RTV 100 mg bid",
"       </td>",
"       <td>",
"        Appears to have better pharmacologic profile and is better tolerated than above",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SQV 1600 mg or 2 gm + RTV 100 mg qd",
"       </td>",
"       <td>",
"        Offers once-daily dosing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Fosamprenavir",
"       </td>",
"       <td>",
"        FPV 1200 mg qd + RTV 200 mg qd",
"       </td>",
"       <td>",
"        The qd boosting regimen is to be used only for treatment na&iuml;ve patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FPV 600 mg bid + RTV 100 mg bid",
"       </td>",
"       <td>",
"        Preferred for protease inhibitor-experienced patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lopinavir",
"       </td>",
"       <td>",
"        LPV 400 mg + RTV 100 mg bid",
"       </td>",
"       <td>",
"        Co-formulated as Kaletra",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atazanavir",
"       </td>",
"       <td>",
"        ATV 300 mg + RTV 100 mg qd",
"       </td>",
"       <td>",
"        Preferred over unboosted ATV 400 mg qd by many experts and necessary when combined with efavirenz or tenofovir. RTV 100 mg does not appear to affect lipid profile.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tipranavir",
"       </td>",
"       <td>",
"        TPV 500 mg bid + RTV 200 mg bid",
"       </td>",
"       <td>",
"        Only approved for use with RTV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Darunavir",
"       </td>",
"       <td>",
"        DRV 800 mg&nbsp;qd + RTV 100 mg qd",
"       </td>",
"       <td>",
"        Highest rate of viral suppression among the boosted PIs, once-daily regimen, and generally well tolerated",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     qd: daily; bid: twice daily; GI: gastrointestinal; RTV: ritonavir.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_19_6460=[""].join("\n");
var outline_f6_19_6460=null;
var title_f6_19_6461="Patient education skills";
var content_f6_19_6461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patient education skills",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"3\" rowspan=\"1\">",
"        Objective 1: Tell a meaningful diagnosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        Step 1 - Ask patient his/her",
"understanding of what the problem or situation is. Or, reflect what",
"you've heard if patient has already stated this.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        Step 2 - Tell patient \"You have... (diagnosis)\" or \"The diagnosis is not clear, but I'm concerned about... (list issues).\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        Step 3 - Ask patient about his/her reaction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Ask about",
"       </td>",
"       <td class=\"subtitle2\">",
"        Description",
"       </td>",
"       <td class=\"subtitle2\">",
"        Examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Knowledge",
"       </td>",
"       <td>",
"        Teach patient about diagnosis. Inquire about patient's understanding of your news. Regulate quantity and level of information.",
"       </td>",
"       <td>",
"        \"What do you already know about this?\" \"What questions do you have?\" \"What do you want to know more about?\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Feelings",
"       </td>",
"       <td>",
"        Inquire about patient's inner state in response to the news, reflect feelings you see/hear (use PEARLS).",
"       </td>",
"       <td>",
"        \"What's your reaction to this?\" \"How are you feeling about this?\" \"You look worried.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beliefs/Meaning",
"       </td>",
"       <td>",
"        Inquire about patient's beliefs about why he/she has the problem or what it means.",
"       </td>",
"       <td>",
"        \"Why do you think you have high blood pressure?\" \"What does it mean to you to hear I'm uncertain about...?\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Expectations",
"       </td>",
"       <td>",
"        Inquire about the patient's expectations of future outcomes.",
"       </td>",
"       <td>",
"        \"What do you see happening when you look to the future?\" \"How do you think things will go for you?\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"3\" rowspan=\"1\">",
"        Objective 2: Negotiate and implement a plan (again use Ask-Tell-Ask format)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Action",
"       </td>",
"       <td class=\"subtitle2\">",
"        Description",
"       </td>",
"       <td class=\"subtitle2\">",
"        Examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ask - existing ideas",
"       </td>",
"       <td>",
"        Find out what he/she has already tried and what ideas he/she has about what the plan should be.",
"       </td>",
"       <td>",
"        \"What have you tried already?\" \"What ideas do you have about what we should do now?\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tell - plan",
"       </td>",
"       <td>",
"        Describe plan, give reasons and expectations, and forecast possible problems.",
"       </td>",
"       <td>",
"        \"I recommend...because...\" \"You can expect...\" \"If...happens, then you should...\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ask - understanding",
"       </td>",
"       <td>",
"        Check patient's understanding and agreement. Inquire about obstacles. Problem-solve and negotiate differences.",
"       </td>",
"       <td>",
"        \"How does this sound to you?\" \"What problems do you anticipate?\" \"Help me understand - what's holding you",
"back?\" \"What would it take for you to be ready?\" \"Let's look together",
"for what might work.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rehearse",
"       </td>",
"       <td>",
"        Check to be sure your and your patient's understanding of the plan are the same.",
"       </td>",
"       <td>",
"        \"Just to be sure we're clear, what would you tell your spouse (or friend) about our plan?\"",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Caution: Patient's unspoken beliefs, fears or lack of commitment frequently appear as defensiveness, resistance or reluctance. Remember, when defensiveness starts, learning stops. For treatment planning, your understanding of such fears and beliefs is as important as your medical expertise. If you see, hear or feel defensiveness in your patient, go back and focus on relationship building. If you're rushed it is better to schedule another visit than to create frustration.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Clark W, Hewson M, Fry M, et al. American Academy on Physician and Patient (AAPP) 1998.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_19_6461=[""].join("\n");
var outline_f6_19_6461=null;
var title_f6_19_6462="Gram stain CSF 5C with answer";
var content_f6_19_6462=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Listeria monocytogenes motility",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 206px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Test for motility of Listeria monocytogenes in semi-solid agar. L. monocytogenes is motile, as can be seen by the growth spreading outward from the central stab.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_19_6462=[""].join("\n");
var outline_f6_19_6462=null;
var title_f6_19_6463="Contents: HIV treatment prevention";
var content_f6_19_6463=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?15/21/15710\">",
"       Infectious Diseases",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       HIV treatment prevention",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			HIV treatment prevention",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Drug resistance",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/46/3814\">",
"           Clinical trials of HIV drug resistance testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/42/32424\">",
"           Drug resistance testing in the clinical management of HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/48/4873\">",
"           Overview of HIV drug resistance testing assays",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/26/34218\">",
"           Primer on interpretation of HIV drug resistance testing",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prevention",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/21/29016\">",
"           Effect of herpes simplex virus on HIV infection: Implications for HIV prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/12/28872\">",
"           Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/24/19848\">",
"           HIV treatment as prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/47/7930\">",
"           Management of healthcare personnel exposed to HIV",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/4/13384\">",
"           Non-antiretroviral interventions to reduce perinatal HIV transmission in the developing world",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/50/26410\">",
"           Nonoccupational exposure to HIV in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/15/34041\">",
"           Pre-exposure prophylaxis against HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/23/29050\">",
"           Prevention of HIV transmission during breastfeeding in resource-limited settings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/14/34024\">",
"           Treatment of drug-resistant genital herpes simplex virus infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/52/41799\">",
"           Treatment of genital herpes simplex virus type 2 in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/35/21049\">",
"           Abacavir hypersensitivity reaction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/34/10794\">",
"           Adverse effects of antiretroviral therapy in developing countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/30/24037\">",
"           Antiretroviral medications in pregnancy: Entry and integrase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/60/16328\">",
"           Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/53/42841\">",
"           Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/24/18825\">",
"           Antiretroviral medications in pregnancy: Protease inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/13/31956\">",
"           Clinical trials of HIV antiretroviral therapy: Agents in advanced stages of development",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/19/37173\">",
"           Clinical trials of HIV antiretroviral therapy: Boosted protease inhibitor monotherapy studies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/9/32918\">",
"           Clinical trials of HIV antiretroviral therapy: CCR5 antagonists",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/1/11286\">",
"           Clinical trials of HIV antiretroviral therapy: Early clinical trials (1987 to 1996)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/34/7720\">",
"           Clinical trials of HIV antiretroviral therapy: Integrase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/4/9287\">",
"           Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/16/17672\">",
"           Clinical trials of HIV antiretroviral therapy: Protease inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/27/14774\">",
"           Clinical trials of HIV antiretroviral therapy: Protease inhibitors versus non-nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/57/33682\">",
"           Clinical trials of HIV antiretroviral therapy: Three versus four-drug regimens",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/5/10325\">",
"           Clinical trials of HIV antiretroviral therapy: Triple regimens using nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/18/3370\">",
"           Considerations prior to initiating antiretroviral therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/61/986\">",
"           Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/29/12759\">",
"           Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/41/9880\">",
"           Evaluation of the treatment-experienced patient with drug-resistant HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/32/40458\">",
"           HIV protease inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/35/23098\">",
"           Immune reconstitution inflammatory syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/40/30345\">",
"           Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/26/36265\">",
"           Modifying HIV antiretroviral therapy regimens",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/17/38167\">",
"           Patient monitoring during HIV antiretroviral therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/56/11144\">",
"           Pharmacology of integrase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/18/37162\">",
"           Pharmacology of non-nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/15/41209\">",
"           Pharmacology of nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/4/15433\">",
"           Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/24/36234\">",
"           Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/21/27994\">",
"           Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/51/10039\">",
"           Structured treatment interruptions in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/6/39018\">",
"           The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/12/29898\">",
"           The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-rich countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/45/33494\">",
"           Treatment and prevention of mitochondrial toxicity in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/5/26713\">",
"           Treatment of HIV-2 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/39/37495\">",
"           Treatment of HIV-infected adults who have trouble swallowing pills: Liquid, chewable, and crushable formulations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/44/25290\">",
"           Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/35/9786\">",
"           When to initiate antiretroviral therapy in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-2E1EB259E1-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f6_19_6463=[""].join("\n");
var outline_f6_19_6463=null;
